Trade Novavax Inc - NVAX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.22 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.07 |
| Open | 4.08 |
| 1-Year Change | -48.87% |
| Day's Range | 3.84 - 4.12 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2024 | 3.94 | -0.18 | -4.37% | 4.12 | 4.12 | 3.83 |
| Apr 24, 2024 | 4.04 | -0.01 | -0.25% | 4.05 | 4.25 | 4.03 |
| Apr 23, 2024 | 4.13 | 0.11 | 2.74% | 4.02 | 4.29 | 3.97 |
| Apr 22, 2024 | 4.02 | 0.07 | 1.77% | 3.95 | 4.05 | 3.84 |
| Apr 19, 2024 | 3.90 | 0.09 | 2.36% | 3.81 | 3.94 | 3.79 |
| Apr 18, 2024 | 3.84 | 0.02 | 0.52% | 3.82 | 3.91 | 3.74 |
| Apr 17, 2024 | 3.84 | -0.04 | -1.03% | 3.88 | 4.01 | 3.81 |
| Apr 16, 2024 | 3.90 | -0.23 | -5.57% | 4.13 | 4.14 | 3.88 |
| Apr 15, 2024 | 4.05 | -0.21 | -4.93% | 4.26 | 4.37 | 4.03 |
| Apr 12, 2024 | 4.26 | 0.04 | 0.95% | 4.22 | 4.40 | 4.17 |
| Apr 11, 2024 | 4.16 | -0.05 | -1.19% | 4.21 | 4.28 | 4.16 |
| Apr 10, 2024 | 4.23 | -0.13 | -2.98% | 4.36 | 4.44 | 4.15 |
| Apr 9, 2024 | 4.37 | 0.02 | 0.46% | 4.35 | 4.58 | 4.32 |
| Apr 8, 2024 | 4.40 | 0.04 | 0.92% | 4.36 | 4.47 | 4.29 |
| Apr 5, 2024 | 4.38 | -0.03 | -0.68% | 4.41 | 4.47 | 4.24 |
| Apr 4, 2024 | 4.40 | -0.07 | -1.57% | 4.47 | 4.67 | 4.37 |
| Apr 3, 2024 | 4.47 | -0.06 | -1.32% | 4.53 | 4.54 | 4.31 |
| Apr 2, 2024 | 4.44 | -0.21 | -4.52% | 4.65 | 4.77 | 4.39 |
| Apr 1, 2024 | 4.60 | -0.17 | -3.56% | 4.77 | 4.79 | 4.54 |
| Mar 28, 2024 | 4.68 | -0.06 | -1.27% | 4.74 | 4.87 | 4.68 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Novavax Company profile
Novavax Inc. (NVAX) is a biotechnology company that specialises in the discovery, development and commercialisation of innovative vaccines that prevent serious infectious diseases.
Headquartered in Maryland, United States, the company was founded in 1987.
It has developed a number of vaccines, including:
The Coronavirus vaccine NVX-CoV2373, currently in phase 3 trials.
The seasonal Influenza vaccine NanoFlu™ for adults over the age of 65, currently also in phase 3 trials.
The respiratory Syncytial Virus (RSV) vaccine ResVax™ for infants and maternal immunisation, currently in phase 3 trials, as well as two RSV F Vaccines, one for older adults (phase 2 trials) and one for children until the age of 5 (phase 1 trials).
The Ebola Virus vaccine Ebola GP Vaccine, currently in phase 1 trials.
The company develops its vaccines using genetically engineered three-dimensional nanostructures of recombinant proteins that are critical to disease pathogenesis.
The company is also working on producing immune-stimulating adjuvants at its wholly owned Swedish subsidiary Novavax AB.
Navavax’s key partners and collaborators include:
The Coalition for Epidemic Preparedness Innovations (CEPI), which has been funding the company to develop and manufacture its coronavirus vaccine candidate.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
The Serum Institute of India (SII).
The 2009 joint venture with India’s privately held pharmaceutical company, Cadila Pharmaceuticals Ltd, to develop Novavax VLP vaccine candidates and some Cadila therapeutic vaccine candidates.
The company (ticker: NVAX) went public on the NASDAQ stock exchange in 1995.
| Industry: | Biotechnology & Medical Research (NEC) |
700 Quince Orchard Road
GAITHERSBURG
MARYLAND 20878
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024
US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com